|Bid||71.04 x 1400|
|Ask||71.07 x 800|
|Day's range||70.89 - 71.36|
|52-week range||68.44 - 82.35|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||25.71|
|Earnings date||28 Oct 2021|
|Forward dividend & yield||2.60 (3.45%)|
|Ex-dividend date||14 Sept 2021|
|1y target est||93.21|
KENILWORTH, N.J., September 17, 2021--Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination with Chemo for Certain Patients with Metastatic TNBC
HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.
Yahoo Finance’s Jessica Smith reports what to expect from Biden’s meeting on vaccine mandates with top business executives.